Ballal Rahul D. has filed 58 insider transactions across 2 companies since January 2023.
Most recent transaction: a grant/award of 17126 shares of Enliven Therapeutics, Inc. ($ELVN) on February 12, 2026.
Activity breakdown: 0 open-market purchases and 15 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 12, 2026 | Enliven Therapeutics, Inc. | $ELVN | Ballal Rahul D. | Not found | A | Stock Option (right to buy) | 17126 | $0.00 | 17,126.0000 | 62,093,795 | 9999.99% | 0.03% |
| Aug. 11, 2025 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Ballal Rahul D. | Director | M | Restricted stock units | 2302 | $0.00 | 0.0000 | 74,254,956,000 | 100.00% | 0.00% |
| Aug. 11, 2025 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Ballal Rahul D. | Director | M | Common stock | 2302 | $0.00 | 12,414.0000 | 74,254,956,000 | 22.77% | 0.00% |
| June 18, 2025 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Ballal Rahul D. | Director | A | Stock options (right to buy) | 15768 | $0.00 | 15,768.0000 | 74,103,192,000 | 9999.99% | 0.00% |
| June 20, 2025 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Ballal Rahul D. | Director | M | Restricted stock units | 2120 | $0.00 | 0.0000 | 74,103,192,000 | 100.00% | 0.00% |
| June 20, 2025 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Ballal Rahul D. | Director | M | Common stock | 2120 | $0.00 | 10,112.0000 | 74,103,192,000 | 26.53% | 0.00% |
| June 18, 2025 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Ballal Rahul D. | Director | A | Restricted stock units | 2816 | $0.00 | 2,816.0000 | 74,103,192,000 | 9999.99% | 0.00% |
| Feb. 6, 2025 | Enliven Therapeutics, Inc. | $ELVN | Ballal Rahul D. | Not found | A | Stock Option (right to buy) | 20491 | $0.00 | 20,491.0000 | 47,072,532 | 9999.99% | 0.04% |
| Nov. 8, 2024 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Ballal Rahul D. | Director | M | Common stock | 10000 | $25.99 | 17,992.0000 | 73,237,954,000 | 125.13% | 0.00% |
| Nov. 8, 2024 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Ballal Rahul D. | Director | S | Common stock | 3571 | $57.24 | 14,421.0000 | 73,237,954,000 | 19.85% | 0.00% |
| Nov. 7, 2024 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Ballal Rahul D. | Director | S | Common stock | 1868 | $54.41 | 7,992.0000 | 73,237,954,000 | 18.95% | 0.00% |
| Nov. 8, 2024 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Ballal Rahul D. | Director | S | Common stock | 4929 | $58.57 | 9,492.0000 | 73,237,954,000 | 34.18% | 0.00% |
| Nov. 8, 2024 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Ballal Rahul D. | Director | M | Stock option (right to buy) | 10000 | $0.00 | 17,947.0000 | 73,237,954,000 | 35.78% | 0.00% |
| Nov. 7, 2024 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Ballal Rahul D. | Director | M | Stock option (right to buy) | 10000 | $0.00 | 27,947.0000 | 73,237,954,000 | 26.35% | 0.00% |
| Nov. 8, 2024 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Ballal Rahul D. | Director | S | Common stock | 1500 | $59.21 | 7,992.0000 | 73,237,954,000 | 15.80% | 0.00% |
| Nov. 7, 2024 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Ballal Rahul D. | Director | M | Common stock | 10000 | $25.99 | 17,992.0000 | 73,237,954,000 | 125.13% | 0.00% |
| Nov. 7, 2024 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Ballal Rahul D. | Director | S | Common stock | 8132 | $53.32 | 9,860.0000 | 73,237,954,000 | 45.20% | 0.00% |
| Oct. 8, 2024 | Enliven Therapeutics, Inc. | $ELVN | Ballal Rahul D. | Not found | M | Common Stock | 6314 | $19.68 | 28,655.0000 | 48,267,458 | 28.26% | 0.01% |
| Oct. 8, 2024 | Enliven Therapeutics, Inc. | $ELVN | Ballal Rahul D. | Not found | M | Common Stock | 4106 | $5.52 | 32,761.0000 | 48,267,458 | 14.33% | 0.01% |
| Oct. 8, 2024 | Enliven Therapeutics, Inc. | $ELVN | Ballal Rahul D. | Not found | M | Stock Option (right to buy) | 4106 | $0.00 | 12,322.0000 | 48,267,458 | 24.99% | 0.01% |
| Oct. 8, 2024 | Enliven Therapeutics, Inc. | $ELVN | Ballal Rahul D. | Not found | S | Common Stock | 10420 | $28.17 | 22,341.0000 | 48,267,458 | 31.81% | 0.02% |
| Oct. 8, 2024 | Enliven Therapeutics, Inc. | $ELVN | Ballal Rahul D. | Not found | M | Stock Option (right to buy) | 6314 | $0.00 | 69,428.0000 | 48,267,458 | 8.34% | 0.01% |
| Aug. 11, 2024 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Ballal Rahul D. | Director | M | Common stock | 2302 | $0.00 | 7,992.0000 | 73,091,490,000 | 40.46% | 0.00% |
| Aug. 11, 2024 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Ballal Rahul D. | Director | M | Restricted stock units | 2302 | $0.00 | 2,302.0000 | 73,091,490,000 | 50.00% | 0.00% |
| June 20, 2024 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Ballal Rahul D. | Director | A | Restricted stock units | 2120 | $0.00 | 2,120.0000 | 72,967,922,000 | 9999.99% | 0.00% |
| June 20, 2024 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Ballal Rahul D. | Director | A | Stock options (right to buy) | 11774 | $0.00 | 11,774.0000 | 72,967,922,000 | 9999.99% | 0.00% |
| June 13, 2024 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Ballal Rahul D. | Director | M | Common stock | 3388 | $0.00 | 5,690.0000 | 72,967,922,000 | 147.18% | 0.00% |
| June 13, 2024 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Ballal Rahul D. | Director | M | Restricted stock units | 3388 | $0.00 | 0.0000 | 72,967,922,000 | 100.00% | 0.00% |
| April 11, 2024 | Enliven Therapeutics, Inc. | $ELVN | Ballal Rahul D. | Not found | M | Stock Option (right to buy) | 48820 | $0.00 | 0.0000 | 35,546,215 | 100.00% | 0.14% |
| April 10, 2024 | Enliven Therapeutics, Inc. | $ELVN | Ballal Rahul D. | Not found | M | Common Stock | 13600 | $12.60 | 35,941.0000 | 35,546,215 | 60.87% | 0.04% |
| April 10, 2024 | Enliven Therapeutics, Inc. | $ELVN | Ballal Rahul D. | Not found | S | Common Stock | 13600 | $21.01 | 22,341.0000 | 35,546,215 | 37.84% | 0.04% |
| April 11, 2024 | Enliven Therapeutics, Inc. | $ELVN | Ballal Rahul D. | Not found | M | Common Stock | 48820 | $12.60 | 71,161.0000 | 35,546,215 | 218.52% | 0.14% |
| April 11, 2024 | Enliven Therapeutics, Inc. | $ELVN | Ballal Rahul D. | Not found | M | Common Stock | 4580 | $19.68 | 75,741.0000 | 35,546,215 | 6.44% | 0.01% |
| April 11, 2024 | Enliven Therapeutics, Inc. | $ELVN | Ballal Rahul D. | Not found | S | Common Stock | 30300 | $23.14 | 45,441.0000 | 35,546,215 | 40.00% | 0.09% |
| April 11, 2024 | Enliven Therapeutics, Inc. | $ELVN | Ballal Rahul D. | Not found | S | Common Stock | 20032 | $25.00 | 25,409.0000 | 35,546,215 | 44.08% | 0.06% |
| April 11, 2024 | Enliven Therapeutics, Inc. | $ELVN | Ballal Rahul D. | Not found | S | Common Stock | 3068 | $25.21 | 22,341.0000 | 35,546,215 | 12.07% | 0.01% |
| April 10, 2024 | Enliven Therapeutics, Inc. | $ELVN | Ballal Rahul D. | Not found | M | Stock Option (right to buy) | 13600 | $0.00 | 48,820.0000 | 35,546,215 | 21.79% | 0.04% |
| April 11, 2024 | Enliven Therapeutics, Inc. | $ELVN | Ballal Rahul D. | Not found | M | Stock Option (right to buy) | 4580 | $0.00 | 75,742.0000 | 35,546,215 | 5.70% | 0.01% |
| April 4, 2024 | Enliven Therapeutics, Inc. | $ELVN | Ballal Rahul D. | Not found | S | Common Stock | 3485 | $19.15 | 22,341.0000 | 35,546,215 | 13.49% | 0.01% |
| April 4, 2024 | Enliven Therapeutics, Inc. | $ELVN | Ballal Rahul D. | Not found | M | Common Stock | 3485 | $12.60 | 25,826.0000 | 35,546,215 | 15.60% | 0.01% |
| April 4, 2024 | Enliven Therapeutics, Inc. | $ELVN | Ballal Rahul D. | Not found | M | Stock Option (right to buy) | 3485 | $0.00 | 62,420.0000 | 35,546,215 | 5.29% | 0.01% |
| April 1, 2024 | Enliven Therapeutics, Inc. | $ELVN | Ballal Rahul D. | Not found | S | Common Stock | 3237 | $19.08 | 22,341.0000 | 35,546,215 | 12.66% | 0.01% |
| April 1, 2024 | Enliven Therapeutics, Inc. | $ELVN | Ballal Rahul D. | Not found | M | Common Stock | 94 | $12.60 | 22,435.0000 | 35,546,215 | 0.42% | 0.00% |
| April 1, 2024 | Enliven Therapeutics, Inc. | $ELVN | Ballal Rahul D. | Not found | M | Common Stock | 3143 | $5.52 | 25,578.0000 | 35,546,215 | 14.01% | 0.01% |
| April 1, 2024 | Enliven Therapeutics, Inc. | $ELVN | Ballal Rahul D. | Not found | M | Stock Option (right to buy) | 3143 | $0.00 | 16,428.0000 | 35,546,215 | 16.06% | 0.01% |
| April 1, 2024 | Enliven Therapeutics, Inc. | $ELVN | Ballal Rahul D. | Not found | M | Stock Option (right to buy) | 94 | $0.00 | 65,905.0000 | 35,546,215 | 0.14% | 0.00% |
| March 20, 2024 | Enliven Therapeutics, Inc. | $ELVN | Ballal Rahul D. | Not found | M | Common Stock | 13278 | $5.52 | 35,619.0000 | 35,546,215 | 59.43% | 0.04% |
| March 20, 2024 | Enliven Therapeutics, Inc. | $ELVN | Ballal Rahul D. | Not found | S | Common Stock | 13278 | $19.16 | 22,341.0000 | 35,546,215 | 37.28% | 0.04% |
| March 20, 2024 | Enliven Therapeutics, Inc. | $ELVN | Ballal Rahul D. | Not found | M | Stock Option (right to buy) | 13278 | $0.00 | 19,571.0000 | 35,546,215 | 40.42% | 0.04% |
| Feb. 13, 2024 | Enliven Therapeutics, Inc. | $ELVN | Ballal Rahul D. | Not found | A | Stock Option (right to buy) | 23364 | $0.00 | 23,364.0000 | 35,546,215 | 9999.99% | 0.07% |
| Feb. 13, 2024 | Enliven Therapeutics, Inc. | $ELVN | Ballal Rahul D. | Not found | A | Stock Option (right to buy) | 16835 | $0.00 | 16,835.0000 | 35,546,215 | 9999.99% | 0.05% |
| Aug. 11, 2023 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Ballal Rahul D. | Director | M | Common stock | 2302 | $0.00 | 2,302.0000 | 71,256,118 | 9999.99% | 0.00% |
| Aug. 11, 2023 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Ballal Rahul D. | Director | M | Restricted stock units | 2302 | $0.00 | 4,604.0000 | 71,256,118 | 33.33% | 0.00% |
| June 13, 2023 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Ballal Rahul D. | Director | A | Stock options (right to buy) | 18958 | $0.00 | 18,958.0000 | 71,256,118 | 9999.99% | 0.03% |
| June 13, 2023 | AGIOS PHARMACEUTICALS, INC. | $AGIO | Ballal Rahul D. | Director | A | Restricted stock units | 3388 | $0.00 | 3,388.0000 | 71,256,118 | 9999.99% | 0.00% |
| Feb. 23, 2023 | Enliven Therapeutics, Inc. | $ELVN | Ballal Rahul D. | Director | A | Stock Option (right to buy) | 27567 | $0.00 | 27,567.0000 | 0 | 9999.99% | 0.00% |
| Feb. 22, 2023 | Enliven Therapeutics, Inc. | $ELVN | Ballal Rahul D. | Chief Executive Officer | S | Common Stock | 32861 | $4.66 | 87,835.0000 | 0 | 27.23% | 0.00% |
| Jan. 30, 2023 | Enliven Therapeutics, Inc. | $ELVN | Ballal Rahul D. | Chief Executive Officer | S | Common Stock | 11313 | $3.91 | 120,696.0000 | 0 | 8.57% | 0.00% |